Nucleoside Cell Factory Synthesis Service
Advantages of Cell Factory for Nucleoside Synthesis
The fusion of a nitrogenous base with a sugar moiety, usually ribose or deoxyribose, is used in the production of nucleosides. This fusion can occur spontaneously within cells during nucleotide biosynthesis or in a laboratory. Enzymes aid in the synthesis of nucleosides by catalyzing the glycosidic connection between the nitrogenous base and the sugar. Chemical procedures can be used in the laboratory to synthesize nucleosides. Uridine, a pyrimidine nucleoside, is widely used in the pharmaceutical industry. A recent research emphasis is on uracil cell factory manufacturing, with CRISPR/Cas9-mediated chromosomal integration functioning as an effective technique for developing appropriate cell factories for this purpose.
Key Technologies
We leverage metabolic engineering of recombinant bacteria equipped with high-efficiency nucleoside-synthesizing enzymes, utilizing CRISPR/Cas9-mediated chromosomal integration for precise strain development. Our technology optimizes growth conditions and metabolic pathways to enable scalable, sustainable nucleoside production for pharmaceutical applications, minimizing environmental impact while ensuring high yields.
Precision Nucleotides, Engineered Cells
Nucleosides and nucleoside derivatives, integral components of antiviral and anticancer medications, are often synthesized using Chemical Methods. However, this approach involves hazardous compounds, leading to environmental harm. Enzymatic synthesis, like the production of 5-methyluridine, is an alternative, but bacterial cell requirements limit its scalability. Cell factories offer a novel avenue for nucleoside manufacturing. Leveraging our robust experimental platform, CD BioGlyco employs recombinant bacteria with potent nucleoside-producing enzymes for cell factory-based nucleoside and analog production. Our services encompass the Technology Development Phase and scalable production, ensuring clients' needs are met. We also extend Nucleotide Synthesis Services, including Chemical Synthesis, Microbial Synthesis, and Enzymatic Digestion, ensuring comprehensive support for diverse research and industrial applications.
It is critical to emphasize that the success of nucleoside synthesis utilizing a cell factory is dependent on meticulous strain engineering, growth environment optimization, and efficient metabolic pathway design. Furthermore, sophisticated techniques like CRISPR/Cas9-Mediated Genome Editing can aid in the construction of high-yielding cell factories for nucleoside manufacturing.
Workflow
Our nucleoside cell factory synthesis service follows a systematic and optimized workflow designed for efficiency and high-yield production:
- Strain Selection and Initial Engineering
We begin by selecting a suitable microbial host, often Escherichia coli, due to its well-understood genetics and robust growth characteristics. Initial engineering focuses on introducing essential biosynthetic pathways, such as integrating multi-gene operons into the host chromosome to establish foundational nucleoside synthesis capabilities.
- Catabolism Pathway Blockade
A crucial step involves identifying and knocking out genes responsible for the degradation of the target nucleoside monomer. This prevents the breakdown of the synthesized product and significantly enhances its accumulation.
- Precursor Supply Optimization
We then focus on enhancing the cellular supply of key metabolic precursors. This involves genetic modifications such as overexpressing rate-limiting enzymes (e.g., CPS) and deleting genes that compete for these precursors (e.g., argF, iclR, thrA). This strategy ensures a robust flow of building blocks towards the desired nucleoside synthesis pathway.
- Product Transport System Enhancement
To maximize the extracellular yield, we modify or delete genes encoding nucleoside transport proteins to facilitate the efficient secretion of the synthesized nucleoside monomers from the cell into the culture medium.
- Fermentation Optimization and Scale-up
The engineered strains undergo rigorous fermentation optimization in controlled bioreactor environments. This involves fine-tuning culture conditions such as media composition, pH, temperature, and aeration rates to achieve optimal growth and maximum product titer and productivity in fed-batch fermentation.
Publication Data
DOI.: 10.1186/s12934-024-02452-8
Journal: Microbial Cell Factories
IF: 4.9
Published: 2024
Results: This study describes the use of combinatorial metabolic engineering in Escherichia coli MG1655 to significantly increase guanosine production. The researchers first chromosomally integrated Bacillus subtilis's purine synthesis operon (Bspur) and overexpressed phosphoribosyl pyrophosphate synthase (prs), while knocking out degradation genes (deoD, ppnP, gsk). They then attenuated the adenosine branch pathway (modified purA), eliminated feedback inhibition by deleting purR, and redirected metabolic flux by disrupting glycolysis/ED pathways (pfkA, edd, eda knockout with glpX overexpression) while rebalancing redox cofactors. Finally, transporter engineering (nupG deletion + nepI overexpression) and strengthening the guanosine synthesis pathway (overexpressing guaAB) further boosted production. The optimized strain MQ39 achieved a guanosine titer of 289.8 mg/L in shake-flask fed-batch fermentation after 72 hours, demonstrating the effectiveness of this systematic approach.
Applications
- Nucleosides are essential components of DNA and RNA, making them crucial for developing antiviral, anticancer, and antifungal drugs. Cell factories can produce nucleosides that serve as precursors for these pharmaceuticals.
- Nucleosides are used in diagnostic tests, such as the polymerase chain reaction (PCR), for amplifying and detecting DNA or RNA sequences. Cell factories can produce nucleosides used as substrates in such assays.
- Nucleosides are used in the production of recombinant proteins and monoclonal antibodies. Nucleoside synthesis in cell factories can support these processes by providing essential building blocks.
- Nucleosides are widely used as research tools in various biological studies, including molecular biology and genetics. Cell factory-produced nucleosides can provide researchers with a convenient and cost-effective source.
Advantages
- We offer custom engineering strain development services for our clients according to their needs, which is a preparation for the cell factory synthesis services.
- We employ a good lab team that offers high-quality production outcomes.
- Our service team consistently provides exceptional client support, offering prompt and helpful assistance to address client needs and inquiries.
Frequently Asked Questions
Associated Services
Beyond precision nucleoside synthesis via our nucleoside cell factory synthesis, we empower next-stage functionalization through specialized Glycogene Engineering Service. Harnessing these enzymatic tools unlocks tailored glycoconjugate synthesis:
Glucosyltransferase Engineering Service
Build glucose-linked nucleosides for targeted oligosaccharide/prodrug applications.
Galactosyltransferase Engineering Service
Design galactosyl-adducted compounds oligosaccharide/prodrug applications.
Mannosyltransferase Engineering Service
Engineer mannose-functionalized analogs for vaccine adjuvants and lectin-targeted delivery.
CD BioGlyco provides cell factory synthesis services for synthesizing nucleosides, and we have a high-level lab to process high-quality synthesis experiments. Please feel free to contact us for more detailed information.
Reference
- Zhang, K.; et al. Efficient production of guanosine in Escherichia coli by combinatorial metabolic engineering. Microbial Cell Factories. 2024, 23(1): 182. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




